We are live on ! Find out more
IVM

InterWest Venture Management Portfolio holdings

AUM $20.6M
1-Year Est. Return 48.5%
This Fund
S&P 500
This Quarter Est. Return
-19.45%
1 Year Est. Return
+48.5%
3 Year Est. Return
-57.65%
5 Year Est. Return
-76.52%
10 Year Est. Return
–
AUM
$241M
AUM Growth
-$75.5M
Cap. Flow
-$12.5M
Cap. Flow %
-5.2%
Top 10 Hldgs %
100%
Holding
11
New
1
Increased
2
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
SERA icon
Sera Prognostics
SERA
+$25.1M
2
GKOS icon
Glaukos
GKOS
+$216K
3
DARE icon
Dare Bioscience
DARE
+$19.2K

Top Sells

Rank Stock Value
1
PMVP icon
PMV Pharmaceuticals
PMVP
+$35.1M
2
CDTX
Cidara Therapeutics
CDTX
+$2.74M

Sector Composition

Rank Sector Weight
1 Healthcare 70.51%
2 Technology 16.64%
3 Consumer Discretionary 12.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PMVP icon
1
PMV Pharmaceuticals
PMVP
$62.9M
$115M 47.76%
3,869,911
-1,100,000
-22% -$35.1M
AI icon
2
C3.ai
AI
$1.37B
$40.2M 16.64%
866,774
– –
REAL icon
3
The RealReal
REAL
$1.4B
$31M 12.85%
2,354,080
– –
SERA icon
4
Sera Prognostics
SERA
$80.3M
$26.8M 11.12%
+2,416,241
New +$25.1M
GKOS icon
5
Glaukos
GKOS
$8.92B
$16.9M 6.99%
350,264
+3,900
+1% +$216K
EIGR
6
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$5.11M 2.12%
25,497
– –
AGTC
7
DELISTED
Applied Genetic Technologies Corporation
AGTC
$4.23M 1.75%
1,404,515
– –
VERO
8
DELISTED
Venus Concept
VERO
$1.65M 0.68%
3,992
– –
XENE icon
9
Xenon Pharmaceuticals
XENE
$6.36B
$127K 0.05%
8,293
– –
DARE icon
10
Dare Bioscience
DARE
$19.8M
$104K 0.04%
5,172
+975
+23% +$19.2K
CDTX
11
DELISTED
Cidara Therapeutics
CDTX
– –
-67,841
Closed -$2.74M

Similar funds

RCP
Rho Capital Partners New York $20.4M AUM
LUGPI
Lightspeed Ultimate General Partner IX Menlo Park, California $20.3M AUM 4.78% 1-Year Est. Return
SIC
Starr International Company Zug, Switzerland $19.9M AUM 39.69% 1-Year Est. Return
DOS
David O. Sacks $19.8M AUM 4.02% 1-Year Est. Return
AA
Antipodean Advisors New York $19.5M AUM 6.21% 1-Year Est. Return
CVSCT
C.V. Starr & Co Trust New York $19.4M AUM 28.57% 1-Year Est. Return
VNB
Virginia National Bank Charlottesville, Virginia $21.9M AUM 12.04% 1-Year Est. Return
BEP
Brookside Equity Partners Stamford, Connecticut $22.5M AUM 62.43% 1-Year Est. Return

InterWest Venture Management's Q3 2021 Portfolio in Review

As of Q3 2021, InterWest Venture Management held 11 positions worth $241M, down 24% from $317M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

InterWest Venture Management withdrew a net $12.5M in Q3 2021, closing 1 position and reducing 1 holding. Its most notable exit was Cidara Therapeutics, an estimated $2.74M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, up from 68% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, InterWest Venture Management opened a new position in Sera Prognostics worth $26.8M.

  • InterWest Venture Management's largest Q3 2021 buy was Sera Prognostics: 2,416,241 shares worth $26.8M.
  • InterWest Venture Management added most to Glaukos in Q3 2021, an estimated $216K increase.
  • InterWest Venture Management's biggest Q3 2021 reduction was PMV Pharmaceuticals, cutting an estimated $35.1M.
  • InterWest Venture Management fully exited Cidara Therapeutics in Q3 2021, selling an estimated $2.74M.
  • InterWest Venture Management's ten largest holdings make up 100% of its $241M portfolio in Q3 2021.
  • InterWest Venture Management opened 1 new position and closed 1 in Q3 2021.
  • InterWest Venture Management's portfolio value fell 24% quarter-over-quarter to $241M.

Based on InterWest Venture Management's 13F filing for Q3 2021, filed 19 Oct 2021.